Incidence Rates and Risk Factors of
CDI
Clostridioides difficile infection
hematopoietic stem cell transplantation
solid organ transplantation
Journal
Open forum infectious diseases
ISSN: 2328-8957
Titre abrégé: Open Forum Infect Dis
Pays: United States
ID NLM: 101637045
Informations de publication
Date de publication:
Apr 2019
Apr 2019
Historique:
received:
25
11
2018
accepted:
15
02
2019
entrez:
6
4
2019
pubmed:
6
4
2019
medline:
6
4
2019
Statut:
epublish
Résumé
Transplant recipients are an immunologically vulnerable patient group and are at elevated risk of Adults undergoing solid organ (SOT) and hematopoietic stem cell transplant (HSCT) from January 2010 to February 2017 at Rigshospitalet, University of Copenhagen, Denmark, were retrospectively included. Using nationwide data capture of all CDI cases, the incidence and risk factors of CDI were assessed. A total of 1687 patients underwent SOT or HSCT (1114 and 573, respectively), with a median follow-up time (interquartile range) of 1.95 (0.52-4.11) years. CDI was diagnosed in 15% (164) and 20% (114) of the SOT and HSCT recipients, respectively. CDI rates were highest in the 30 days post-transplant for both SOT and HSCT (adjusted incidence rate ratio [aIRR], 6.64; 95% confidence interval [CI], 4.37-10.10; and aIRR, 2.85; 95% CI, 1.83-4.43, respectively, compared with 31-180 days). For SOT recipients, pretransplant CDI and liver and lung transplant were associated with a higher risk of CDI in the first 30 days post-transplant, whereas age and liver transplant were risk factors in the later period. Among HSCT recipients, myeloablative conditioning and a higher Charlson Comorbidity Index were associated with a higher risk of CDI in the early period but not in the late period. Using nationwide data, we show a high incidence of CDI among transplant recipients. Importantly, we also find that risk factors can vary relative to time post-transplant.
Sections du résumé
BACKGROUND
BACKGROUND
Transplant recipients are an immunologically vulnerable patient group and are at elevated risk of
METHODS
METHODS
Adults undergoing solid organ (SOT) and hematopoietic stem cell transplant (HSCT) from January 2010 to February 2017 at Rigshospitalet, University of Copenhagen, Denmark, were retrospectively included. Using nationwide data capture of all CDI cases, the incidence and risk factors of CDI were assessed.
RESULTS
RESULTS
A total of 1687 patients underwent SOT or HSCT (1114 and 573, respectively), with a median follow-up time (interquartile range) of 1.95 (0.52-4.11) years. CDI was diagnosed in 15% (164) and 20% (114) of the SOT and HSCT recipients, respectively. CDI rates were highest in the 30 days post-transplant for both SOT and HSCT (adjusted incidence rate ratio [aIRR], 6.64; 95% confidence interval [CI], 4.37-10.10; and aIRR, 2.85; 95% CI, 1.83-4.43, respectively, compared with 31-180 days). For SOT recipients, pretransplant CDI and liver and lung transplant were associated with a higher risk of CDI in the first 30 days post-transplant, whereas age and liver transplant were risk factors in the later period. Among HSCT recipients, myeloablative conditioning and a higher Charlson Comorbidity Index were associated with a higher risk of CDI in the early period but not in the late period.
CONCLUSIONS
CONCLUSIONS
Using nationwide data, we show a high incidence of CDI among transplant recipients. Importantly, we also find that risk factors can vary relative to time post-transplant.
Identifiants
pubmed: 30949533
doi: 10.1093/ofid/ofz086
pii: ofz086
pmc: PMC6441586
doi:
Types de publication
Journal Article
Langues
eng
Pagination
ofz086Références
Med Care. 2005 Nov;43(11):1130-9
pubmed: 16224307
Clin Transplant. 2011 Jan-Feb;25(1):E82-7
pubmed: 20973823
Am J Epidemiol. 2011 Mar 15;173(6):676-82
pubmed: 21330339
N Engl J Med. 2011 Nov 3;365(18):1693-703
pubmed: 22047560
Biol Blood Marrow Transplant. 2012 Aug;18(8):1295-301
pubmed: 22387347
Clin Infect Dis. 2012 Apr;54(8):1053-63
pubmed: 22412059
Transplantation. 2012 May 27;93(10):1051-7
pubmed: 22441318
Transpl Infect Dis. 2012 Oct;14(5):540-7
pubmed: 22726461
Biol Blood Marrow Transplant. 2014 Jun;20(6):823-8
pubmed: 24607558
PLoS One. 2014 Mar 24;9(3):e90158
pubmed: 24662889
Int J Hematol. 2014 Jun;99(6):758-65
pubmed: 24715522
Biol Blood Marrow Transplant. 2014 Oct;20(10):1650-4
pubmed: 24914822
Biol Blood Marrow Transplant. 2014 Oct;20(10):1626-33
pubmed: 24973628
Lancet Infect Dis. 2014 Dec;14(12):1208-19
pubmed: 25455988
N Engl J Med. 2015 Feb 26;372(9):825-34
pubmed: 25714160
PLoS One. 2015 Apr 17;10(4):e0124483
pubmed: 25886133
Am J Transplant. 2015 Nov;15(11):2970-7
pubmed: 26484839
Am J Hematol. 2016 Mar;91(3):291-4
pubmed: 26661725
Bone Marrow Transplant. 2016 May;51(5):713-7
pubmed: 26726944
Clin Transplant. 2016 Jun;30(6):703-8
pubmed: 27019071
Transplantation. 2016 Sep;100(9):1939-43
pubmed: 27379554
Transpl Infect Dis. 2017 Feb;19(1):null
pubmed: 27943498
Transpl Infect Dis. 2017 Feb;19(1):null
pubmed: 27943501
Transpl Infect Dis. 2017 Jun;19(3):null
pubmed: 28273393
Open Forum Infect Dis. 2017 Mar 22;4(2):ofx050
pubmed: 28491889
J Infect Dis. 2017 Apr 1;215(7):1117-1123
pubmed: 28498996
Curr Opin Organ Transplant. 2017 Aug;22(4):314-319
pubmed: 28542111
Epidemiol Infect. 2017 Sep;145(12):2594-2602
pubmed: 28689506
Am J Transplant. 2018 Jul;18(7):1745-1754
pubmed: 29349869
Transplantation. 2018 Sep;102(9):1576-1581
pubmed: 29620613